-
22 July 2026
-
22 July 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. ...
-
01 July 2026
-
01 July 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and o...
-
19 September 2025
-
19 September 2025
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Paris, France – 19 September 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval for Bylvay® (odevixibat) for the treatment of pruritus associated with...
-
15 May 2026
-
15 May 2026
Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement in patients with PBC
PARIS, FRANCE, 15 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the latest data on IQIRVO® (elafibranor) demonstrating clinically meaningful improvements in ALP, a surrogate marker of primary biliary cholangitis (PBC) disease progression, a...
-
13 July 2026
-
13 July 2026
IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study
PARIS, FRANCE, 13 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase IIIb ELSPIRE trial evaluating IQIRVO® (elafibranor) in patients with PBC with an Alkaline Phosphatase (ALP) 1-1.67 times the upper limit of normal (x ULN) met t...
-
28 May 2026
-
28 May 2026
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
PARIS, FRANCE, 28 MAY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of new late-breaking results from the ELATIVE® Phase III trial and two real-world studies at the European Association for the Study of the Liver (EASL) congre...
-
07 November 2025
-
07 November 2025
-
24 April 2025
-
24 April 2025
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
PARIS, FRANCE, 24 April 2025 Ipsen (Euronext: IPN; ADR: IPSEY) will be presenting data from the late-breaking abstract on elafibranor in the investigational Phase II ELMWOOD study at the European Association for the Study of the Liver (EASL) congress as an...
-
12 March 2026
-
12 March 2026
Ipsen appoints Michelle C. Werner as EVP, President of North America
PARIS, FRANCE, 12 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Michelle C. Werner as Executive Vice President (EVP), President of North America, effective 23 March 2026. Michelle will serve on the Executive Leadership T...
-
19 December 2025
-
19 December 2025
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)
PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia os...